GlassScriptPhysician profile
Sandra R Layne
NPI 1891878419
$9,311.62
in general payments reported to CMS, 2019-2025
24 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $854 · 2021: $1,708 · 2022: $1,832 · 2023: $1,294 · 2024: $1,409 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,292.64 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,227.63 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $938.54 | 2020-2022 | |
| Braintree Laboratories, INC. | $544.64 | 2019-2025 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $409.90 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $389.97 | 2019-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $379.35 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $369.40 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $317.78 | 2019-2023 | Clenpiq |
| Redhill Biopharma INC. | $299.69 | 2020-2024 | Talicia |
| Janssen Biotech, INC. | $284.93 | 2022-2025 | Stelara, Tremfya, Remicade |
| Merck Sharp & Dohme LLC | $219.49 | 2021-2024 | Dificid |
| Allergan, INC. | $139.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $64.28 | 2024-2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $61.66 | 2021-2023 | Zeposia |
| Genzyme Corporation | $51.86 | 2023 | |
| Alfasigma USA, INC. | $44.09 | 2020 | |
| Intra-Sana Laboratories | $41.38 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Aimmune Therapeutics, INC. | $25.77 | 2025 | Zenpep |
| Cumberland Pharmaceuticals, INC. | $23.40 | 2020-2021 | |
| Daiichi Sankyo INC. | $22.83 | 2020 | |
| Concordia Pharmaceuticals INC. | $19.82 | 2019 | |
| Qol Medical, LLC | $18.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Layne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.